Glycogen storage disease type II (English Wikipedia)

Analysis of information sources in references of the Wikipedia article "Glycogen storage disease type II" in English language version.

refsWebsite

Global rank English rank

26nih.gov

4^th place

15doi.org

2^nd place

7web.archive.org

1^st place

5semanticscholar.org

11^th place

8^th place

4europa.eu

68^th place

117^th place

3fda.gov

447^th place

338^th place

1campaign-archive1.com

low place

1agsdus.org

low place

1wsj.com

79^th place

65^th place

1cadth.ca

low place

1globenewswire.com

2,614^th place

1,549^th place

1amicusrx.com

low place

1mda.org

low place

1sec.gov

572^nd place

436^th place

1medscape.com

719^th place

636^th place

1worldcat.org

5^th place

1ctvnews.ca

768^th place

482^nd place

1nytimes.com

7^th place

agsdus.org

"Type II Glycogen Storage Disease". The Association for Glycogen Storage Disease. Archived from the original on June 23, 2012. Retrieved May 22, 2012.

amicusrx.com

ir.amicusrx.com

"Amicus Therapeutics Announces Approval and Launch of New Pompe Disease Therapy in the European Union".

cadth.ca

"Canadian Common Drug Review Recommendations on Public Funding for Myozyme" (PDF). Archived from the original (PDF) on January 29, 2019. Retrieved June 23, 2007.

campaign-archive1.com

us5.campaign-archive1.com

Genetic, Alliance. "Federal Advisory Committee Recommends Pompe Disease for Newborn Screening". Genetic Alliance. Retrieved May 17, 2013.

ctvnews.ca

"Rare, deadly genetic disease successfully treated in utero for first time". CTVNews. November 9, 2022. Retrieved November 10, 2022.

doi.org

Prater SN, Banugaria SG, DeArmey SM, Botha EG, Stege EM, Case LE, Jones HN, Phornphutkul C, Wang RY, Young SP, Kishnani PS (September 2012). "The emerging phenotype of long-term survivors with infantile Pompe disease". Genet Med. 14 (9): 800–10. doi:10.1038/gim.2012.44. PMC 3947503. PMID 22538254.
Bali, Deeksha (February 15, 2012). "Predicting Cross Reactive Immunological Material (CRIM) Status in Pompe Disease Using GAA Mutations: Lessons Learned from 10 Years of Clinical Laboratory Testing Experience". American Journal of Medical Genetics. 160C (1): 40–49. doi:10.1002/ajmg.c.31319. PMC 3278076. PMID 22252923.
Yang, Chia-Feng; Yang, Chen Chang; Liao, Hsuan-Chieh; Huang, Ling-Yi; Chiang, Chuan-Chi; Ho, Hui-Chen; Lai, Chih-Jou; Chu, Tzu-Hung; Yang, Tsui-Feng; Hsu, Ting-Rong; Soong, Wen-Jue; Niu, Dau-Ming (February 2016). "Very Early Treatment for Infantile-Onset Pompe Disease Contributes to Better Outcomes". The Journal of Pediatrics. 169: 174–180.e1. doi:10.1016/j.jpeds.2015.10.078. PMID 26685070. S2CID 4504302.
Matsuoka, Takashi; Miwa, Yoshiyuki; Tajika, Makiko; Sawada, Madoka; Fujimaki, Koichiro; Soga, Takashi; Tomita, Hideshi; Uemura, Shigeru; Nishino, Ichizo; Fukuda, Tokiko; Sugie, Hideo; Kosuga, Motomichi; Okuyama, Torayuki; Umeda, Yoh (November 18, 2016). "Divergent clinical outcomes of alpha-glucosidase enzyme replacement therapy in two siblings with infantile-onset Pompe disease treated in the symptomatic or pre-symptomatic state". Molecular Genetics and Metabolism Reports. 9: 98–105. doi:10.1016/j.ymgmr.2016.11.001. PMC 5121151. PMID 27896132.
Wagner KR (2007). "Enzyme replacement for infantile Pompe disease: the first step toward a cure". Neurology. 68 (2): 88–89. doi:10.1212/01.wnl.0000253226.13795.40. PMID 17210887. S2CID 42540784.
Chien YH; Lee, NC; Thurberg, BL; Chiang, SC; Zhang, XK; Keutzer, J; Huang, AC; Wu, MH; et al. (2009). "Pompe disease in infants: improving the prognosis by newborn screening and early treatment". Pediatrics. 124 (6): e1116–25. doi:10.1542/peds.2008-3667. PMID 19948615.
Amalfitano A, Bengur AR, Morse RP, Majure JM, Case LE, Veerling DL, Mackey J, Kishnani P, Smith W, McVie-Wylie A, Sullivan JA, Hoganson GE, Phillips JA, Schaefer GB, Charrow J, Ware RE, Bossen EH, Chen YT (2001). "Recombinant human acid alpha-glucosidase enzyme therapy for infantile glycogen storage disease type II: results of a phase I/II clinical trial". Genetics in Medicine. 3 (2): 132–38. doi:10.1097/00125817-200103000-00008. PMID 11286229.
Mendelsohn NJ; Messinger, YH; Rosenberg, AS; Kishnani, PS (2009). "Elimination of antibodies to recombinant enzyme in Pompe disease". N Engl J Med. 360 (2): 194–95. doi:10.1056/NEJMc0806809. PMID 19129538.
Van der Ploeg AT (2010). "A randomized study of alucosidase alfa in late-onset Pompe disease". N Engl J Med. 362 (15): 1396–1406. doi:10.1056/NEJMoa0909859. PMID 20393176. S2CID 5216178.
Khan, Aneal; Ramage, Barbara; Robu, Ion; Benard, Laura (2009). "Side-Alternating Vibration Training Improves Muscle Performance in a Patient with Late-Onset Pompe Disease". Case Reports in Medicine. 2009: 741087. doi:10.1155/2009/741087. PMC 2729289. PMID 19710926.
Colburn R; Lapidus D (2024). "An analysis of Pompe newborn screening data: a new prevalence at birth, insight and discussion". Frontiers in Pediatrics. 11. doi:10.3389/fped.2023.1221140. PMC 10810242. PMID 38274468.
Van der Ploeg AT, Kroos MA, Willemsen R, Brons NH, Reuser AJ (February 1991). "Intravenous administration of phosphorylated acid alpha-glucosidase leads to uptake of enzyme in heart and skeletal muscle of mice". J. Clin. Invest. 87 (2): 513–18. doi:10.1172/JCI115025. PMC 296338. PMID 1991835.
Kikuchi T, Yang HW, Pennybacker M, et al. (February 1998). "Clinical and metabolic correction of Pompe disease by enzyme therapy in acid maltase-deficient quail". J. Clin. Invest. 101 (4): 827–33. doi:10.1172/JCI1722. PMC 508631. PMID 9466978.
Van den Hout H, Reuser AJ, Vulto AG, Loonen MC, Cromme-Dijkhuis A, Van der Ploeg AT (July 2000). "Recombinant human alpha-glucosidase from rabbit milk in Pompe patients". Lancet. 356 (9227): 397–98. doi:10.1016/S0140-6736(00)02533-2. PMID 10972374. S2CID 54268990.
Cohen, Jennifer L.; Chakraborty, Pranesh; Fung-Kee-Fung, Karen; Schwab, Marisa E.; Bali, Deeksha; Young, Sarah P.; Gelb, Michael H.; Khaledi, Hamid; DiBattista, Alicia; Smallshaw, Stacey; Moretti, Felipe; Wong, Derek; Lacroix, Catherine; El Demellawy, Dina; Strickland, Kyle C.; Lougheed, Jane; Moon-Grady, Anita; Lianoglou, Billie R.; Harmatz, Paul; Kishnani, Priya S.; MacKenzie, Tippi C. (November 9, 2022). "In Utero Enzyme-Replacement Therapy for Infantile-Onset Pompe's Disease". New England Journal of Medicine. 387 (23). Massachusetts Medical Society: 2150–8. doi:10.1056/nejmoa2200587. ISSN 0028-4793. PMC 10794051. PMID 36351280. S2CID 253444841.

europa.eu

ema.europa.eu

"Nexviadyme: Pending EC decision". European Medicines Agency (EMA). July 23, 2021. Archived from the original on July 28, 2021. Retrieved July 27, 2021.
"Nexviadyme EPAR". European Medicines Agency (EMA). July 20, 2021. Retrieved December 18, 2022.
"Pombiliti: Pending EC decision". European Medicines Agency (EMA). December 16, 2022. Archived from the original on December 18, 2022. Retrieved December 18, 2022.
EMA (December 9, 2022). "Pombiliti". European Medicines Agency. Retrieved September 29, 2023.

fda.gov

"FDA Approval News for Myozyme". Food and Drug Administration. Archived from the original on May 19, 2006. Retrieved December 16, 2009.
"FDA Approves New Treatment for Pompe Disease". U.S. Food and Drug Administration (FDA) (Press release). August 6, 2021. Archived from the original on August 6, 2021. Retrieved August 6, 2021. This article incorporates text from this source, which is in the public domain.

accessdata.fda.gov

"Drug Approval Package: Myozyme (Alglucosidase Alfa) NDA #125141". U.S. Food and Drug Administration (FDA). Archived from the original on July 8, 2016. Retrieved December 18, 2022.

globenewswire.com

"FDA approves Nexviazyme (avalglucosidase alfa-ngpt), an important new treatment option for late-onset Pompe disease" (Press release). Sanofi. August 6, 2021. Retrieved August 6, 2021 – via GlobeNewswire.

mda.org

"Muscular Dystrophy Association Celebrates FDA Approval of Amicus Therapeutics' Pombiliti + Opfolda for Treatment of Pompe Disease". Muscular Dystrophy Association. September 28, 2023. Retrieved September 29, 2023.

medscape.com

emedicine.medscape.com

Genetics of Glycogen-Storage Disease Type II (Pompe Disease) at eMedicine

nih.gov

pubmed.ncbi.nlm.nih.gov

Prater SN, Banugaria SG, DeArmey SM, Botha EG, Stege EM, Case LE, Jones HN, Phornphutkul C, Wang RY, Young SP, Kishnani PS (September 2012). "The emerging phenotype of long-term survivors with infantile Pompe disease". Genet Med. 14 (9): 800–10. doi:10.1038/gim.2012.44. PMC 3947503. PMID 22538254.
Bali, Deeksha (February 15, 2012). "Predicting Cross Reactive Immunological Material (CRIM) Status in Pompe Disease Using GAA Mutations: Lessons Learned from 10 Years of Clinical Laboratory Testing Experience". American Journal of Medical Genetics. 160C (1): 40–49. doi:10.1002/ajmg.c.31319. PMC 3278076. PMID 22252923.
Yang, Chia-Feng; Yang, Chen Chang; Liao, Hsuan-Chieh; Huang, Ling-Yi; Chiang, Chuan-Chi; Ho, Hui-Chen; Lai, Chih-Jou; Chu, Tzu-Hung; Yang, Tsui-Feng; Hsu, Ting-Rong; Soong, Wen-Jue; Niu, Dau-Ming (February 2016). "Very Early Treatment for Infantile-Onset Pompe Disease Contributes to Better Outcomes". The Journal of Pediatrics. 169: 174–180.e1. doi:10.1016/j.jpeds.2015.10.078. PMID 26685070. S2CID 4504302.
Matsuoka, Takashi; Miwa, Yoshiyuki; Tajika, Makiko; Sawada, Madoka; Fujimaki, Koichiro; Soga, Takashi; Tomita, Hideshi; Uemura, Shigeru; Nishino, Ichizo; Fukuda, Tokiko; Sugie, Hideo; Kosuga, Motomichi; Okuyama, Torayuki; Umeda, Yoh (November 18, 2016). "Divergent clinical outcomes of alpha-glucosidase enzyme replacement therapy in two siblings with infantile-onset Pompe disease treated in the symptomatic or pre-symptomatic state". Molecular Genetics and Metabolism Reports. 9: 98–105. doi:10.1016/j.ymgmr.2016.11.001. PMC 5121151. PMID 27896132.
Wagner KR (2007). "Enzyme replacement for infantile Pompe disease: the first step toward a cure". Neurology. 68 (2): 88–89. doi:10.1212/01.wnl.0000253226.13795.40. PMID 17210887. S2CID 42540784.
Chien YH; Lee, NC; Thurberg, BL; Chiang, SC; Zhang, XK; Keutzer, J; Huang, AC; Wu, MH; et al. (2009). "Pompe disease in infants: improving the prognosis by newborn screening and early treatment". Pediatrics. 124 (6): e1116–25. doi:10.1542/peds.2008-3667. PMID 19948615.
Amalfitano A, Bengur AR, Morse RP, Majure JM, Case LE, Veerling DL, Mackey J, Kishnani P, Smith W, McVie-Wylie A, Sullivan JA, Hoganson GE, Phillips JA, Schaefer GB, Charrow J, Ware RE, Bossen EH, Chen YT (2001). "Recombinant human acid alpha-glucosidase enzyme therapy for infantile glycogen storage disease type II: results of a phase I/II clinical trial". Genetics in Medicine. 3 (2): 132–38. doi:10.1097/00125817-200103000-00008. PMID 11286229.
Mendelsohn NJ; Messinger, YH; Rosenberg, AS; Kishnani, PS (2009). "Elimination of antibodies to recombinant enzyme in Pompe disease". N Engl J Med. 360 (2): 194–95. doi:10.1056/NEJMc0806809. PMID 19129538.
Van der Ploeg AT (2010). "A randomized study of alucosidase alfa in late-onset Pompe disease". N Engl J Med. 362 (15): 1396–1406. doi:10.1056/NEJMoa0909859. PMID 20393176. S2CID 5216178.
Khan, Aneal; Ramage, Barbara; Robu, Ion; Benard, Laura (2009). "Side-Alternating Vibration Training Improves Muscle Performance in a Patient with Late-Onset Pompe Disease". Case Reports in Medicine. 2009: 741087. doi:10.1155/2009/741087. PMC 2729289. PMID 19710926.
Colburn R; Lapidus D (2024). "An analysis of Pompe newborn screening data: a new prevalence at birth, insight and discussion". Frontiers in Pediatrics. 11. doi:10.3389/fped.2023.1221140. PMC 10810242. PMID 38274468.
Van der Ploeg AT, Kroos MA, Willemsen R, Brons NH, Reuser AJ (February 1991). "Intravenous administration of phosphorylated acid alpha-glucosidase leads to uptake of enzyme in heart and skeletal muscle of mice". J. Clin. Invest. 87 (2): 513–18. doi:10.1172/JCI115025. PMC 296338. PMID 1991835.
Kikuchi T, Yang HW, Pennybacker M, et al. (February 1998). "Clinical and metabolic correction of Pompe disease by enzyme therapy in acid maltase-deficient quail". J. Clin. Invest. 101 (4): 827–33. doi:10.1172/JCI1722. PMC 508631. PMID 9466978.
Van den Hout H, Reuser AJ, Vulto AG, Loonen MC, Cromme-Dijkhuis A, Van der Ploeg AT (July 2000). "Recombinant human alpha-glucosidase from rabbit milk in Pompe patients". Lancet. 356 (9227): 397–98. doi:10.1016/S0140-6736(00)02533-2. PMID 10972374. S2CID 54268990.
Cohen, Jennifer L.; Chakraborty, Pranesh; Fung-Kee-Fung, Karen; Schwab, Marisa E.; Bali, Deeksha; Young, Sarah P.; Gelb, Michael H.; Khaledi, Hamid; DiBattista, Alicia; Smallshaw, Stacey; Moretti, Felipe; Wong, Derek; Lacroix, Catherine; El Demellawy, Dina; Strickland, Kyle C.; Lougheed, Jane; Moon-Grady, Anita; Lianoglou, Billie R.; Harmatz, Paul; Kishnani, Priya S.; MacKenzie, Tippi C. (November 9, 2022). "In Utero Enzyme-Replacement Therapy for Infantile-Onset Pompe's Disease". New England Journal of Medicine. 387 (23). Massachusetts Medical Society: 2150–8. doi:10.1056/nejmoa2200587. ISSN 0028-4793. PMC 10794051. PMID 36351280. S2CID 253444841.

ncbi.nlm.nih.gov

Prater SN, Banugaria SG, DeArmey SM, Botha EG, Stege EM, Case LE, Jones HN, Phornphutkul C, Wang RY, Young SP, Kishnani PS (September 2012). "The emerging phenotype of long-term survivors with infantile Pompe disease". Genet Med. 14 (9): 800–10. doi:10.1038/gim.2012.44. PMC 3947503. PMID 22538254.
Bali, Deeksha (February 15, 2012). "Predicting Cross Reactive Immunological Material (CRIM) Status in Pompe Disease Using GAA Mutations: Lessons Learned from 10 Years of Clinical Laboratory Testing Experience". American Journal of Medical Genetics. 160C (1): 40–49. doi:10.1002/ajmg.c.31319. PMC 3278076. PMID 22252923.
Matsuoka, Takashi; Miwa, Yoshiyuki; Tajika, Makiko; Sawada, Madoka; Fujimaki, Koichiro; Soga, Takashi; Tomita, Hideshi; Uemura, Shigeru; Nishino, Ichizo; Fukuda, Tokiko; Sugie, Hideo; Kosuga, Motomichi; Okuyama, Torayuki; Umeda, Yoh (November 18, 2016). "Divergent clinical outcomes of alpha-glucosidase enzyme replacement therapy in two siblings with infantile-onset Pompe disease treated in the symptomatic or pre-symptomatic state". Molecular Genetics and Metabolism Reports. 9: 98–105. doi:10.1016/j.ymgmr.2016.11.001. PMC 5121151. PMID 27896132.
Khan, Aneal; Ramage, Barbara; Robu, Ion; Benard, Laura (2009). "Side-Alternating Vibration Training Improves Muscle Performance in a Patient with Late-Onset Pompe Disease". Case Reports in Medicine. 2009: 741087. doi:10.1155/2009/741087. PMC 2729289. PMID 19710926.
Colburn R; Lapidus D (2024). "An analysis of Pompe newborn screening data: a new prevalence at birth, insight and discussion". Frontiers in Pediatrics. 11. doi:10.3389/fped.2023.1221140. PMC 10810242. PMID 38274468.
Van der Ploeg AT, Kroos MA, Willemsen R, Brons NH, Reuser AJ (February 1991). "Intravenous administration of phosphorylated acid alpha-glucosidase leads to uptake of enzyme in heart and skeletal muscle of mice". J. Clin. Invest. 87 (2): 513–18. doi:10.1172/JCI115025. PMC 296338. PMID 1991835.
Kikuchi T, Yang HW, Pennybacker M, et al. (February 1998). "Clinical and metabolic correction of Pompe disease by enzyme therapy in acid maltase-deficient quail". J. Clin. Invest. 101 (4): 827–33. doi:10.1172/JCI1722. PMC 508631. PMID 9466978.
Cohen, Jennifer L.; Chakraborty, Pranesh; Fung-Kee-Fung, Karen; Schwab, Marisa E.; Bali, Deeksha; Young, Sarah P.; Gelb, Michael H.; Khaledi, Hamid; DiBattista, Alicia; Smallshaw, Stacey; Moretti, Felipe; Wong, Derek; Lacroix, Catherine; El Demellawy, Dina; Strickland, Kyle C.; Lougheed, Jane; Moon-Grady, Anita; Lianoglou, Billie R.; Harmatz, Paul; Kishnani, Priya S.; MacKenzie, Tippi C. (November 9, 2022). "In Utero Enzyme-Replacement Therapy for Infantile-Onset Pompe's Disease". New England Journal of Medicine. 387 (23). Massachusetts Medical Society: 2150–8. doi:10.1056/nejmoa2200587. ISSN 0028-4793. PMC 10794051. PMID 36351280. S2CID 253444841.

dailymed.nlm.nih.gov

"Myozyme (alglucosidase alfa) Injectable for intravenous infusion Initial U.S. Approval: 2006". DailyMed. Retrieved December 18, 2022.
"Lumizyme- alglucosidase alfa injection, powder, for solution". DailyMed. February 22, 2020. Retrieved August 14, 2020.

ghr.nlm.nih.gov

Pompe disease at NLM Genetics Home Reference

nytimes.com

Kolata, Gina (November 9, 2022). "The Disease Took Zara, Then Sara. Could Ayla Be Saved?". The New York Times. Retrieved November 26, 2023.

sec.gov

"Amicus Therapeutics Announces FDA Approval and Launch of New Treatment for Pompe Disease". www.sec.gov. Retrieved September 29, 2023.

semanticscholar.org

api.semanticscholar.org

Yang, Chia-Feng; Yang, Chen Chang; Liao, Hsuan-Chieh; Huang, Ling-Yi; Chiang, Chuan-Chi; Ho, Hui-Chen; Lai, Chih-Jou; Chu, Tzu-Hung; Yang, Tsui-Feng; Hsu, Ting-Rong; Soong, Wen-Jue; Niu, Dau-Ming (February 2016). "Very Early Treatment for Infantile-Onset Pompe Disease Contributes to Better Outcomes". The Journal of Pediatrics. 169: 174–180.e1. doi:10.1016/j.jpeds.2015.10.078. PMID 26685070. S2CID 4504302.
Wagner KR (2007). "Enzyme replacement for infantile Pompe disease: the first step toward a cure". Neurology. 68 (2): 88–89. doi:10.1212/01.wnl.0000253226.13795.40. PMID 17210887. S2CID 42540784.
Van der Ploeg AT (2010). "A randomized study of alucosidase alfa in late-onset Pompe disease". N Engl J Med. 362 (15): 1396–1406. doi:10.1056/NEJMoa0909859. PMID 20393176. S2CID 5216178.
Van den Hout H, Reuser AJ, Vulto AG, Loonen MC, Cromme-Dijkhuis A, Van der Ploeg AT (July 2000). "Recombinant human alpha-glucosidase from rabbit milk in Pompe patients". Lancet. 356 (9227): 397–98. doi:10.1016/S0140-6736(00)02533-2. PMID 10972374. S2CID 54268990.
Cohen, Jennifer L.; Chakraborty, Pranesh; Fung-Kee-Fung, Karen; Schwab, Marisa E.; Bali, Deeksha; Young, Sarah P.; Gelb, Michael H.; Khaledi, Hamid; DiBattista, Alicia; Smallshaw, Stacey; Moretti, Felipe; Wong, Derek; Lacroix, Catherine; El Demellawy, Dina; Strickland, Kyle C.; Lougheed, Jane; Moon-Grady, Anita; Lianoglou, Billie R.; Harmatz, Paul; Kishnani, Priya S.; MacKenzie, Tippi C. (November 9, 2022). "In Utero Enzyme-Replacement Therapy for Infantile-Onset Pompe's Disease". New England Journal of Medicine. 387 (23). Massachusetts Medical Society: 2150–8. doi:10.1056/nejmoa2200587. ISSN 0028-4793. PMC 10794051. PMID 36351280. S2CID 253444841.

web.archive.org

"Type II Glycogen Storage Disease". The Association for Glycogen Storage Disease. Archived from the original on June 23, 2012. Retrieved May 22, 2012.
"Drug Approval Package: Myozyme (Alglucosidase Alfa) NDA #125141". U.S. Food and Drug Administration (FDA). Archived from the original on July 8, 2016. Retrieved December 18, 2022.
"FDA Approval News for Myozyme". Food and Drug Administration. Archived from the original on May 19, 2006. Retrieved December 16, 2009.
"Canadian Common Drug Review Recommendations on Public Funding for Myozyme" (PDF). Archived from the original (PDF) on January 29, 2019. Retrieved June 23, 2007.
"Nexviadyme: Pending EC decision". European Medicines Agency (EMA). July 23, 2021. Archived from the original on July 28, 2021. Retrieved July 27, 2021.
"FDA Approves New Treatment for Pompe Disease". U.S. Food and Drug Administration (FDA) (Press release). August 6, 2021. Archived from the original on August 6, 2021. Retrieved August 6, 2021. This article incorporates text from this source, which is in the public domain.
"Pombiliti: Pending EC decision". European Medicines Agency (EMA). December 16, 2022. Archived from the original on December 18, 2022. Retrieved December 18, 2022.

worldcat.org

search.worldcat.org

Cohen, Jennifer L.; Chakraborty, Pranesh; Fung-Kee-Fung, Karen; Schwab, Marisa E.; Bali, Deeksha; Young, Sarah P.; Gelb, Michael H.; Khaledi, Hamid; DiBattista, Alicia; Smallshaw, Stacey; Moretti, Felipe; Wong, Derek; Lacroix, Catherine; El Demellawy, Dina; Strickland, Kyle C.; Lougheed, Jane; Moon-Grady, Anita; Lianoglou, Billie R.; Harmatz, Paul; Kishnani, Priya S.; MacKenzie, Tippi C. (November 9, 2022). "In Utero Enzyme-Replacement Therapy for Infantile-Onset Pompe's Disease". New England Journal of Medicine. 387 (23). Massachusetts Medical Society: 2150–8. doi:10.1056/nejmoa2200587. ISSN 0028-4793. PMC 10794051. PMID 36351280. S2CID 253444841.

wsj.com

Anand G (September 18, 2007). "As Costs Rise, New Medicines Face Pushback". The Wall Street Journal. Retrieved December 18, 2022.